



RESEARCH

Open Access

Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer

Farbod Shojaei^{1*}, Nathan Scott⁴, Xiaolin Kang¹, Patrick B Lappin³, Amanda A Fitzgerald⁴, Shannon Karlicek¹, Brett H Simmons¹, Aidong Wu², Joseph H Lee¹, Simon Bergqvist¹ and Eugenia Kraynov²

Abstract

Osteopontin (OPN), also known as SPP1 (secreted phosphoprotein), is an integrin binding glyco-phosphoprotein produced by a variety of tissues. In cancer patients expression of OPN has been associated with poor prognosis in several tumor types including breast, lung, and colorectal cancers. Despite wide expression in tumor cells and stroma, there is limited evidence supporting role of OPN in tumor progression and metastasis. Using phage display technology we identified a high affinity anti-OPN monoclonal antibody (hereafter AOM1). The binding site for AOM1 was identified as SWYGLRSKS sequence which is immediately adjacent to the RGD motif and also spans the thrombin cleavage site of the human OPN. AOM1 efficiently inhibited OPNa binding to recombinant integrin $\alpha v \beta 3$ with an IC₅₀ of 65 nM. Due to its unique binding site, AOM1 is capable of inhibiting OPN cleavage by thrombin which has been shown to produce an OPN fragment that is biologically more active than the full length OPN. Screening of human cell lines identified tumor cells with increased expression of OPN receptors ($\alpha v \beta 3$ and CD44v6) such as mesothelioma, hepatocellular carcinoma, breast, and non-small cell lung adenocarcinoma (NSCLC). CD44v6 and $\alpha v \beta 3$ were also found to be highly enriched in the monocyte, but not lymphocyte, subset of human peripheral blood mononuclear cells (hPBMCs). *In vitro*, OPNa induced migration of both tumor and hPBMCs in a transwell migration assay. AOM1 significantly blocked cell migration further validating its specificity for the ligand. OPN was found to be enriched in mouse plasma in a number of pre-clinical tumor model of non-small cell lung cancers. To assess the role of OPN in tumor growth and metastasis and to evaluate a potential therapeutic indication for AOM1, we employed a *Kras*^{G12D-LSL}*p53*^{fl/fl} subcutaneously implanted *in vivo* model of NSCLC which possesses a high capacity to metastasize into the lung. Our data indicated that treatment of tumor bearing mice with AOM1 as a single agent or in combination with Carboplatin significantly inhibited growth of large metastatic tumors in the lung further supporting a role for OPN in tumor metastasis and progression.

Introduction

OPN is a multifunctional protein involved in several pathological processes such as inflammation and cancer [1]. As an acidic glycoposphoprotein, OPN contains a RGD (arginine-glycine-aspartate) integrin binding motif, a hydrophobic leader sequence (indicative of its secretory characteristic), a thrombin cleavage site adjacent to RGD domain, and a cell attachment sequence [2]. OPN has been found to be present in three forms in tissues and fluids: i) an intracellular protein in complex with hyaluronan-CD44-ERM (ezrin/radixin/moesin) that is involved in migration of tumor and stromal cells [3]; ii)

an extracellular protein that is abundant at mineralized tissues [4]; iii) a secreted protein that is found in fluids isolated from metastatic tumors [5] and also found in organs such as placenta [6,7], breast [8], and testes [9]. At the protein synthesis level, OPN undergoes extensive post-translational modification including phosphorylation and glycosylation [10]. Additionally, there are three splice variants of OPN (OPNa, OPNb, and OPNc) that may have distinct characteristics in different tissues and tumor types [11]. For example, OPN-c has been suggested to be expressed in invasive breast tumors and is highly correlated with patient's survival in HER-2 breast patients [12]. Irrespective of OPN isoform, a series of other studies have suggested a role for plasma OPN as a biomarker of tumor progression in colon [13,14], lung [15], and prostate cancers [16,17].

* Correspondence: Farbodshojaei@hotmail.com

¹Pfizer Global Research and Development, Department of Oncology, La Jolla, CA, USA

Full list of author information is available at the end of the article

The RGD sequence in OPN protein enables it to bind to CD44-ERM and several integrins including $\alpha_v\beta_1$, $\alpha_v\beta_3$, and $\alpha_v\beta_5$ [18]. Given the wide expression of integrins and CD44, both cancer cells as well as stromal compartment are targeted by OPN in the tumor mass. Binding of OPN to the above receptors on tumor cells triggers downstream signaling pathways including Ras, Akt, MAPK, Src, FAK and NF-KB [1] that collectively lead to the following in tumor cells: i) invasion to ECM (extracellular matrix) mainly via upregulation of MMPs [19] (matrix metalloproteinases) and uPAs [20] (urokinase plasminogen activator) by OPN; ii) increased migration and adhesion of tumor cells [21]; iii) inhibition of cell death likely through upregulation of anti-apoptosis mediators such as GAS6 [22]; and iv) development of pre-metastatic niche [23]. Additionally, tumor stroma such as endothelial cells [18] and immune infiltrating cells [24,25] (particularly monocytes) express OPN receptors. Angiogenesis is proven to be a critical component of tumor mass by supplying oxygen and nutrients for cancer cells [26]. Angiogenesis in the tumor is induced by OPN directly by binding to $\alpha_v\beta_3$, and/or indirectly via upregulation of VEGF (vascular endothelial growth factor) [27,28]. Additionally, OPN may suppress immune response via inhibition of iNOS (inducible nitric oxide synthase) in immune infiltrating cells further creating a conducive microenvironment for growth and invasion of tumor cells [29,30]. It is noteworthy to mention that cleavage by thrombin enhances biological activity of OPN [31] through increased exposure of N-terminal domain to integrin binding sites [32] and/or via formation of a complex between the c-terminal domain and cyclophilin and CD147 resulting in the activation of Akt1-2 and MMP-2 [33]. VEGF may accelerate thrombin activity to generate cleaved-OPN that in turn results in increased migration of endothelial cells [34].

To further understand the role of OPN in tumor progression, we screened phage display libraries and identified a monoclonal anti-OPN antibody (AOM1) capable of neutralizing human and mouse OPN. In vitro, AOM1 inhibited OPN-induced migration of tumor cells and monocytes. Furthermore, AOM1, as a single agent or in combination with a cytotoxic agent, inhibited growth of large tumors in the lung in a metastatic model of NSCLC indicating a role for OPN in lung metastasis.

Materials and methods

Inhibition of thrombin mediated degradation of human OPN

Ability of AOM1 to inhibit OPN cleavage by thrombin was evaluated in a western blot assay. Reaction buffer included PBS pH 7.2 containing 2 mM $MgCl_2$ and 0.2 mM $MnCl_2$. Both AOM1 and the control antibodies

were added to human OPN (2.2 $\mu g/ml$) and reaction buffer to a total volume of 900 μl . Anti-OPN antibody concentration was titrated from 3 nM to 1000 nM. OPN and AOM1 were pre-incubated at 37°C on a rotary shaker for 1 hour to allow association to occur. Next, 100 μl of 50% thrombin-agarose slurry (in reaction buffer, Sigma, CA) was added to the reaction mixture and were incubated for 2 hours at 37°C on a rotary shaker. Reaction mixture supernatant was removed and analyzed by SDS-PAGE and western blot using a mouse anti-human OPN antibody (34E3, IBL, Japan) specific to the N-terminal fragment of thrombin cleaved OPN. Intensity of the western blot staining of the thrombin cleaved N-terminal fragment was compared at different concentrations of AOM1 to approximate an IC50 for thrombin cleavage inhibition.

Integrin binding inhibition assay

Immunosorbent plates (COSTAR Corning, CA) were coated with 100 $\mu l/well$ integrin $\alpha_v\beta_3$ (10 $\mu g/ml$, R&D System, MN) in Buffer 1 (PBS 7.2 with 0.2 mM $MnCl_2$ and 2 mM $MgCl_2$) for overnight at 4°C. Plates were then washed three times with Buffer 1 and non-specific binding sites blocked with 200 $\mu l/well$ of blocking buffer (3% BSA in Buffer 1) for two hours at 37°C. Next, plates were washed three times with Buffer 1 and 100 μl of OPN/test antibody mixture was applied to the plate surface. The OPN/test antibody mixture was prepared as follows. Human OPN (R&D systems, MN) was maintained at a constant final concentration (6 $\mu g/ml$) in the blocking buffer. OPN was mixed with either AOM1 or control antibody. Antibody concentrations were titrated from 10 μM in a three-fold dilution series to approximately 0.1 nM. Human OPN and test antibody were pre-incubated for 1 hour at room temperature on a rotary mixer before being applied to the $\alpha_v\beta_3$ coated ELISA plates. After a washing step (3 times with Buffer 1 + 0.05% Tween-20 and three times with Buffer 1 alone), rabbit polyclonal anti-human OPN antibody (O-17, IBL, Japan) was added to the plates (100 $\mu l/well$) at a concentration of 4 $\mu g/ml$ for 1 hour at room temperature. Plates were then washed (3 times with Buffer 1 + 0.05% Tween-20 and 3 times with Buffer 1 alone) and goat-anti-rabbit antibody (Fc specific) HRP conjugate (Jackson Immunoresearch, PA) was added to each well (100 $\mu l/well$, 1 in 5000 dilution in Block Buffer) for 1 hour at room temperature. Following final washes (3 times with Buffer 1 + 0.05% Tween-20 and 3 times with Buffer 1 alone) ELISA was developed with 100 $\mu l/well$ BM Blue POD substrate (Roche, NJ) and the colorimetric reaction was stopped with 100 $\mu l/well$ 0.2 M H_2SO_4 . Absorbance at 450 nm was measured using a Spectromax plate reader (Molecular Devices, CA) and analysis was conducted using Microsoft Excel Data-

Analysis Add-In fitting IC50 curves to a 4-parameter sigmoidal saturation binding model.

Selectivity of AOM1 for OPN

EIA/RIA plates (Corning, NY) were coated with 1 mg/ml of RGD-motif containing protein which included OPN, Thrombospondin, Vitronectin, CollIA1 or Fibronectin (R&D Systems, MN) in Buffer 1 (PBS pH 7.2 containing 2 mM MgCl₂ and 0.2 mM MnCl₂ for 16 hours at 4°C). Plates were washed three times with Buffer 1 and were blocked with commercially available Blocking buffer (3% BSA (Rockland, PA) in Buffer 1) followed by washing three times with Buffer 1 and AOM1 was added at 0, 0.1, 1, 10, and 1000 nM in blocking buffer, and incubated at RT for 1 hr. Plates were washed (3 times with Buffer 1 + 0.05% Tween-20 and three times with Buffer 1 alone). Goat Anti-Human IgG (Fc) Peroxidase Conjugate (Jackson ImmunoResearch, PA) was added (1 in 5000 in block buffer) and plates were incubated at RT for 1 h followed by a wash (3 times with Buffer 1 + 0.05% Tween-20 and three times with Buffer 1 alone). BM Blue Solution (Roche, NJ) was used to develop the assay and quenched with 0.18 M HR₂SOR₄. Absorbance at 450 nm was detected using a Spectramax plate reader (Molecular Devices, CA) and data were analyzed using Microsoft Excel.

Characterization of AOM1 Fab binding to OPN

Binding of Fab fragment of AOM1 to recombinant OPN was determined using surface plasmon resonance (SPR) analysis on a Biacore 3000 instrument (GE Healthcare, CA). Recombinant OPNs (human: 1433-OP-050/CF; mouse 441-OP-050/CF; R&D System, MN) was immobilized on a CM5 biosensor chip using standard EDC/NHS amine coupling chemistry, at 25°C using a 1 μM in 10 mM sodium acetate pH 5.0. Experiments were carried out in a buffer containing 10 mM HEPES pH 7.4, 150 mM NaCl, 0.005% P20 at 25°C using a two-fold dilution series of the Fab. Data were analyzed using the Scrubber2 software (BioLogic Software, Pty., Australia). Injections were referenced to a blank surface and by a buffer blank. Kinetic characteristics were obtained from a fit to a simple kinetic binding model using the Scrubber2 program software (BioLogic Software, Pty., Australia).

Epitope mapping

Epitope mapping studies were carried out using an overlapping series of synthetic peptides (CPC Scientific, CA) designed based on the primary sequence of OPN. Peptides corresponding to the region 143-172 of human OPN are listed below:

1. 143EVFTPVVPTVDTYDGRGDSVYGLRSKSKK172
2. 143EVFTPVVPTVDTYDGRGDSVYGLR167

3. 143EVFTPVVPTVDTYD156
4. 156DGRGDSVYGLRSKSKK172

Binding of each peptide was determined to the immobilized anti-OPN antibody by SPR. The antibody was immobilized on a CM5 chip by standard EDC/NHS amine coupling chemistry, at 25°C using a 1 μM in 10 mM sodium acetate pH 5.0. Peptides were diluted to 5 μM in 10 mM HEPES pH 7.4, 150 mM NaCl, 0.005% P20 and diluted with a two-fold series. The samples were analyzed at a flow rate of 20 μL/min and were injected serially over all four flow cells for a 5 minute association and a 5 minute dissociation. The binding data were fit to a simple equilibrium binding model using Scrubber2 (BioLogic Software, Pty., Australia).

Migration assay was performed in transwell plates (VWR, CA) using standard protocol provided by the manufacturer. All the cell lines (JHH4, MSTO-211H and MDA-MB435) were purchased from ATCC (American Type Culture Collection; VA) and were grown in RPMI (GIBCO BRL, CA) supplemented with 10% FBS (Sigma Aldrich, CA). Cells were harvested from flasks and were placed (5×10^4 Cells in 100 μl plain media) on the top chamber of transwells. Plates were incubated in a cellular incubator for 4 hrs and migrating cells were counted in the bottom well.

To measure migrating hPBMCs, blood samples were taken from healthy individuals under guidelines provided by Pfizer Department of Environmental Health and Safety. Nearly 40 ml blood was collected from a healthy individual in a 4 CPT tube and was spun 20 min at 3000 RPM followed by harvesting PBMCs in 50 ml polypropylene tubes, washing twice in plain RPMI1640 and starvation for 2 hrs at 37°C. Cells were then spiked with AOM1 or control antibody and were incubated at 37°C for 1 hr in a cell incubator. Next, 150 μl of pretreated PBMC in RPMI was added to the top chamber of transwell while bottom wells contained either plain RPMI with or without OPN (R&D System, MN, 5 μg/ml). Plates were incubated in a cell incubator for 4 hrs at 37°C and migratory cells were counted in the bottom well.

Flowcytometry, histology and ELISA

Cells (tumor cells or PBMCs) were stained with anti-CD44v6-APC (R&D System, MN) or anti-αvβ3-PE (R&D System, MN) antibodies using standard protocol provided by the manufacturer. Mouse antibodies (CD44-FITC α_v-APC and β₃-PE) were all purchased from BD Biosciences. All the stained samples were analyzed in a Calibur instrument (BD Biosciences, CA) and data were analyzed in FCS express software (De Novo, CA). Whole lungs were collected from treated animals and were preserved in formalin and embedded in paraffin. Sections of lungs were stained with Hematoxyline and Eosin staining (H&E) to evaluate efficacy of different

treatments on the growth of lung tumors. Plasma samples were collected when mice were euthanized at the end of *in vivo* study and mouse OPN was measured by an ELISA kit (R&D System, MN) using a protocol provided by the manufacturer.

Tumor implantation

Kras^{G12D-LSL}p53^{fl/fl} mice (n = 10) were inhaled intranasally with Adeno-CMV-Cre (2.5 × 10⁷ viral particles, University of Iowa, IO). Using trocar catheter, pieces of tumors were removed from the lungs at 16 weeks post-inhalation and were immediately implanted subcutaneously in Scid/beige mice. Tumor bearing mice (n = 10) were randomized at 8 days post-implantation when tumors reached 200 mm³ using caliper measurement [35]. Randomized animals were treated with vehicle, Carboplatin (25 mg/kg weekly, Hospira, IL), AOM1 (30 mg/kg weekly) and combination of both compounds using intra-peritoneal route of administration. The entire study was terminated when vehicle-treated tumors reached ~2500 mm³. Whole lungs were fixed in formalin, embedded in paraffin and were cut using a microtome machine in the laboratory. Slides from each treatment were stained in H&E (hetoxilin and eosin) and metastasis in each section was assessed by a certified pathologist. Lung lesions were quantified based on size of tumors to small (less than 10 cells) medium (10-200) and large (more than 200 cells).

Results

Development and characterization of AOM1 monoclonal antibody targeting mouse and human OPN


Analysis of aa (amino-acid) sequences of three different isoforms of OPN (a, b and c) provided some clue about common regions between the isotypes in order to identify antibodies potentially capable of binding and neutralizing all forms of OPN (Figure 1A). Consistent with a published report [36], there is a conserved aa sequence in all three isoforms corresponding to binding sites for a series of integrins including $\alpha_4\beta_1$, $\alpha_4\beta_7$, $\alpha_9\beta_1$, $\alpha_9\beta_4$, $\alpha_v\beta_3$, $\alpha_v\beta_1$, $\alpha_v\beta_5$, $\alpha_5\beta_1$ and $\alpha_8\beta_1$ making it an attractive epitope to target with an anti-OPN neutralizing antibody. Screening of phage display libraries identified several antibodies with the potential to bind to the integrin binding sequence of OPN. Further detailed biochemical and cellular characterization led to the discovery of AOM1, a fully human monoclonal antibody with the ability of neutralizing both human and mouse OPN. Species specificity of AOM1 was determined by SPR (surface plasmon resonance) using OPN immobilized on a Biacore chip. AOM1 was found to cross-react with human and mouse OPN (Figure 1.B). Using a Fab fragment of AOM1, affinity of AOM1 to human OPN was measured to be 50 nM. Epitope recognized by AOM1

on human OPN was determined using a series of overlapping synthetic peptides corresponding to the region 143-172 of human OPN. AOM1 binds to SVVYGLRSKS motif which is a binding site for integrins $\alpha_4\beta_1$, $\alpha_4\beta_7$, $\alpha_9\beta_1$, and $\alpha_9\beta_{4R}$ (Figure 1). The epitope is immediately adjacent to the RGD sequence which is the binding site for another family of integrins ($\alpha_v\beta_3$, $\alpha_v\beta_1$, $\alpha_v\beta_5$, $\alpha_5\beta_1$ and $\alpha_8\beta_1$). In addition, the AOM1 binding epitope spans over the main thrombin cleavage site on OPN. The ability of AOM1 to inhibit OPN binding to integrin $\alpha_v\beta_3$ which is considered to be the major receptor by which OPN regulates cancer cell migration and proliferation, and to prevent thrombin-mediated cleavage of OPN was characterized in an ELISA-based and western blot assays, respectively. In both cases AOM1 demonstrated high inhibitory activity (Figure 1B&C). Therefore, this unique binding epitope allows AOM1 to inhibit multiple functional activities of OPN by preventing signaling through integrins as well as blocking cleavage of OPN by thrombin which has been shown to produce functionally more active OPN fragments than the full length molecule. Of note, AOM1 has high selectivity for OPN and does not recognize other RGD containing proteins which is consistent with its binding epitope.

OPN acts as a chemotactic agent for human tumor cells and monocytes

To identify a potential therapeutic indication for AOM1 we first screened a series of human and mouse cancer cells to identify cell lines that express OPN receptors in particular $\alpha_v\beta_3$ and CD44v6. As illustrated in Figure 2A-C, FACS analysis identified at least three cell lines expressing OPN receptors including JHH4, MDA-MB435, and MSTO-211H. Furthermore, transwell assay data showed that these cells were capable of migrating to OPN (5 μ g/ml) indicating a functional relevance for receptor expression in these cells (Figure 2D-F). Treatment with AOM1 (150 μ g/ml) fully inhibited cell migration suggesting that blockade of integrin binding site is sufficient to inhibit cell migration to OPN.

In addition to tumor cells, we investigated expression of OPN receptors in human PBMCs (peripheral blood mononuclear cells; Figure 3A). Flowcytometry data indicated expression of $\alpha_v\beta_3$ and to a lesser extent CD44v6 in the entire human PBMCs (Figure 3B). Further gating on populations of granulocytes and monocytes (GM) vs. lymphocytes showed a greater expression of both receptors in GM compared to lymphocyte subset (Figure 3C). The migration assay supported flowcytometry data since only GM, but not lymphocytes, migrated towards OPN (Figure 3D). Overall, and consistent with published reports [37], we have provided receptor expression and functional data further supporting a role for OPN in tumor growth via affecting both cancer cells and stroma.




OPN is highly enriched in a murine model of NSCLC

In addition to human cells we also analyzed mouse cell lines to identify a preclinical model to test efficacy of AOM1 with specific focus on lung tumors. OPN has been shown to be highly enriched in lung tumors [38]. Surgical removal of primary lung tumors in patients results in a significant reduction in levels of OPN in plasma further indicating a role for OPN as a biomarker of tumor progression in NSCLC [39]. Consistent with these findings, a mass spectrometry method was developed to quantify three different isoforms of OPN (a, b, and c) in plasma samples obtained from NSCLC patients and healthy individuals. Analysis of plasma

samples showed that all three isoforms of OPN were present in healthy individuals but were less abundant than in cancer patients. Of note, elevated OPNa accounted for the majority of the increased total OPN in cancer patients [40].

The $Kras^{G12D-LSL}p53^{fl/fl}$ GEMM (genetically engineered mouse model) represents one of the most relevant models of human NSCLC [41]. Biology of tumor progression and efficacy of therapeutic agents have been extensively studied in this model. Intranasal inhalation of viral particles containing Cre-recombinase results in activation of mutated $Kras^{G12DP}$ and ablation of p53 that in turn lead to tumor formation and progression in



the lung reminiscent of lesions observed in cancer patients with a similar mutation [42]. Therefore, the availability of these mice prompted us to test efficacy of AOM1 on tumor growth and progression. However, repeat-dose treatment of these immuno-competent mice with AOM1, a fully human IgG2, resulted in rapid

clearance of the antibody from plasma possibly due to the development of anti-drug antibodies (no changes in AOM1 clearance was observed following repeated treatment of immune-compromised mice, data not shown). To circumvent this limitation, we modified this tumor model by *de novo* isolating tumors from the lung of




Figure 3 CD44v6 and $\alpha\beta 3$ are highly expressed in granulocyte and monocyte but not lymphocyte subpopulation of hPBMCs. **A** Representative side scatter vs. forward scatter plot of hPBMCs representing populations of lymphocytes (L), granulocytes (G) and monocytes (M). **B&C** Expression of OPN receptors ($\alpha\beta 3$ (B) and CD44v6 (C)) was measured in hPBMCs and was evaluated in L vs. GM subsets. **D** Transwell migration assay in L vs. GM subset indicated that only the latter is capable of migrating toward OPN thus providing a functional relevance of expression of receptors.

Kras^{G12D-LSL}p53^{fl/fl} GEMMs and implanting them subcutaneously (without any *in vitro* manipulation) in immunodeficient scid mice to create KPT (Kras^{G12D-LSL}p53^{fl/fl} Trocar) mice. All the implanted tumors were capable of growth and proliferation in the immunodeficient recipients (Figure 4A). ELISA data showed elevated levels of OPN in plasma in KPT mice suggesting a role for OPN in tumor progression in this model (Figure 4B). FACS data indicated that both tumor cells and PBMCs isolated from animals bearing these tumors express $\alpha\text{v}\beta 3$ and CD44 receptors further supporting a rationale for treatment of sc-tumors with AOM1 (Figure 4C). Analysis of sc tumor volumes did not reveal any significant difference at the primary site of tumor growth in any of the treatment groups (including AOM1 as single agent or in combination with Carboplatin) suggesting that OPN may not play an important role in tumor growth at the primary site of tumorigenesis (Figure 4D).

Lung metastasis is induced by OPN in KPT mice

In addition to primary tumor growth, the sc-implanted tumors had the capacity to metastasize to the lung indicating that tumor pieces from the GEMMs have maintained their invasive capacity. We analyzed metastasis in the lungs and further classified tumor lesions as small, medium, and large according to the size of the lesions (Figure 5A). Pathology analysis indicated that while there was no significant difference in the number of small or medium tumors in the lung, AOM1 as single agent or in combination with Carboplatin significantly inhibited growth of large tumors (Figure 5B). In addition analysis of the frequency of lung metastases showed a significant decrease in the percentage of mice carrying large lung tumors following treatment with AOM1 as compared to the vehicle-treated animals, particularly in combination treatment group (AOM1 plus Carboplatin) where none of the mice carried large tumors as judged by the histological analysis (Figure 5C). These observations suggest a role for OPN as a mediator of metastasis in a preclinical model of NSCLC.

Discussion

Among molecular mediators of tumor growth and progression, OPN represents a complex target/pathway particularly in drug development. OPN has been identified in several pathological tissues (inflammatory, obese, and cancerous) in the organism [1]. OPN expression is elevated during inflammation to recruit macrophages and other immune infiltrating cells. A recent report shows that OPN may play a significant role in obesity through regulation of insulin signaling in liver cells and inflammation [43]. In cancer, OPN is highly expressed in a variety of tumors and appears to be a prognostic factor

correlating with tumor progression in patients. Despite wide expression and involvement in multiple pathological conditions, the lack of OPN in mice is not embryonically lethal nor does it cause a prominent phenotype compared to wild type mice suggesting that alternative mechanisms compensate for the lack of OPN or it may not play a key role in embryonic development [44]. One of the main challenges in characterizing role of OPN in tumor progression is the existence of two distinct families of receptors including integrins and CD44v6 that have the capacity to trigger downstream signaling pathways independent of each other. Therefore, inhibition of one of the two receptors/pathways may not completely suppress OPN signalling and development of therapeutic compounds to inhibit both receptors is extremely challenging if not impossible.

In the tumor mass, OPN is secreted by both stroma and cancer cells [36]. It appears that there are distinct functions for tumor-derived vs. stromal-derived OPN in tumor growth and metastasis. Crawford et al developed a model of cutaneous squamous cell carcinoma in OPN null mice and showed that while the number of metastatic tumors is increased in this model, the size of metastasized tumors was significantly lower compared to corresponding wild type mice [45]. It is suggested that stromal OPN may recruit anti-tumor macrophages resulting in smaller tumor growth [45]. However, other reports in melanoma [46] and breast [47] tumors suggest that host-derived OPN is important for tumor growth and metastasis adding to the complexity of OPN in tumor biology.

Here, we developed an anti-OPN antibody capable of neutralizing human and mouse OPN, and utilized it to investigate the role of OPN in preclinical models with particular focus on lung cancer since a significant amount of data supports a role for OPN in NSCLCs [48]. All three transcripts of OPN have been identified in NSCLC patients and gain-of-function analyses indicate that OPNa, but not OPNb or OPNc, is involved in increased proliferation, migration, and invasion of tumor cells [49]. Serum OPN has been shown to act as a biomarker in lung carcinoma [38,50]. Conversely, reduction in serum OPN (e.g. due to resection of primary tumors) [51] is an indicator of better outcome in NSCLC patients treated with cytotoxic agent [52]. Despite all these reports, it remains to be clearly determined if OPN is a biomarker and/or a driver of tumor progression in NSCLC.

The Kras^{G12D-LSL}p53^{fl/fl} mice [53] is one of the most relevant preclinical models of NSCLC since 20-30% of NSCLC patients carry Kras mutation [54] and 35-60% show genetic aberrations in p53 [55]. Capacity of tumor fragments to engraft in immuno-deficient animals provided an opportunity to test efficacy of AOM1 in




Figure 4 Characterizing OPN and its receptors in mouse NSCLCs. A Development of KPT model. Kras^{G12D-LSL}p53^{fl/fl} (KP) mice were inhaled with Adeno-CMV-Cre at approximately 8 weeks after birth. Lung tumors were inspected at approximately 18 weeks post-inhalation. Pieces of lung tumors were taken from transgenic mice and were implanted subcutaneously (without any in vitro manipulation) into Scid/beige mice using trocar to generate KPT (Kras^{G12D-LSL}p53^{fl/fl} trocar) model as described in the Materials and Methods. **B** Tumor implantation results in increased levels of OPN in the plasma in tumor bearing mice. **C** Using flowcytometry, expression of CD44v6 and αvβ3 was evaluated in KP cells and mPBMCs. Cells were stained with the antibodies as described in materials and methods and data analysis showed greater expression of αvβ3 than CD44 in both KP and mPBMCs. **D** KPT mice were randomized and received treatments (Vehicle, AOM1, Carboplatin and combination) at 8 days post-implantation. Tumors volume were measured twice/week and study was terminated at 27 days after implantation.




Figure 5 AOM1 inhibits growth of large tumors in the lung in a NSCLC tumor. **A** Scid/beige mice were sc implanted with pieces of tumors isolated from lung lesions from $Kras^{G12D-LSLp53^{fl/fl}}$ mice. Implanted mice were randomized at 8 days post-implantation and were treated with vehicle, AOM1, carboplatin and combination of both compounds. Tumor volume was measured using caliper twice per week. At terminal analysis whole lung from each mouse was fixed in formalin and was stained in H&E. Representative images from each treatment are shown. In pathology analysis lung lesions were classified into small (less than 10 cells) medium (10-200) and large (more than 200 cells) size and were quantified in each treatment. **B** Quantifications of lesions in each treatment. Bar graph represents mean number of lesions \pm SEM. **C** Frequency of mice carrying each lesion in each treatment also indicated that AOM1 as single agent or in combination with Carboplatin significantly inhibits percentage of mice carrying large tumors in the lung.

NSCLC tumors. Lack of response to AOM1 in primary tumor growth indicates an overlapping mechanism between OPN and the other tumor-promoting factors. However, inhibition of the growth of metastatic lesions, which had been seeded prior to the initiation of AOM1 treatment, suggests a role for OPN as a mediator of metastasis rather than a regulator of primary tumor growth. Further investigation is needed to unravel details of the role of OPN in lung metastasis. For example, it remains to be determined if OPN promotes seeding of a specific clone of tumor cells that will eventually outgrow to large tumors in the lung or it is required to further promote tumor growth at late stage in the metastatic niche. Alternatively and given our *in vitro* data, OPN may inhibit migration and seeding of clone of tumor cells that may eventually rise to large tumors. Future work in this direction will likely result in an increased understanding of this complex protein that might have some benefits for cancer patients

Abbreviations

OPN: Osteopontin; SPP1: secreted phosphoprotein; RGD: arginine-glycine-aspartate; AOM1: anti-OPN monoclonal antibody; NSCLC: Non-small cell lung adenocarcinoma; hPBMCs: Human peripheral blood mononuclear cells; ERM: ezrin/radixin/moesin; ECM: extracellular matrix; MMPs: matrix metalloproteinases; uPAs: urokinase plasminogen activator; VEGF: vascular endothelial growth factor; iNOS: inducible nitric oxide synthase; SPR: surface plasmon resonance; GEMM: genetically engineered mouse model; KPT: Kras^{G12D+LSL}p53^{fl/fl} Trocar

Author details

¹Pfizer Global Research and Development, Department of Oncology, La Jolla, CA, USA. ²Pfizer Global Research and Development, Department of Pharmacokinetics, Dynamics, and Metabolism, La Jolla, CA, USA. ³Pfizer Global Research and Development, Department of Drug Safety Research & Development, La Jolla, CA, USA. ⁴Pfizer Global Research and Development, Department of Global Biotherapeutics Technologies, Cambridge, MA, USA.

Authors' contributions

FS, NS, SB and EK designed experiments and contributed in execution of studies. XK, AF, SK, BS, AW, JL executed studies and PL provided pathology analyses. FS wrote the manuscript which was edited revised by FS, NS, AF, PL and EK.

Competing interests

All authors are employees and shareholders of Pfizer.

Received: 25 January 2012 Accepted: 23 March 2012

Published: 23 March 2012

References

1. Shevde LA, Das S, Clark DW, Samant RS: **Osteopontin: an effector and an effect of tumor metastasis.** *Curr Mol Med* 2010, **10**:71-81.
2. Fisher LW, Torchia DA, Fohr B, Young MF, Fedarko NS: **Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin.** *Biochem Biophys Res Commun* 2001, **280**:460-465.
3. Weber GF, Ashkar S, Glimcher MJ, Cantor H: **Receptor-ligand interaction between CD44 and osteopontin (Eta-1).** *Science* 1996, **271**:509-512.
4. McKee MD, Nanci A: **Osteopontin: an interfacial extracellular matrix protein in mineralized tissues.** *Connect Tissue Res* 1996, **35**:197-205.
5. Hui EP, Sung FL, Yu BK, Wong CS, Ma BB, Lin X, Chan A, Wong WL, Chan AT: **Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer.** *Clin Cancer Res* 2008, **14**:7080-7087.
6. Siiteri JE, Ensrud KM, Moore A, Hamilton DW: **Identification of osteopontin (OPN) mRNA and protein in the rat testis and epididymis, and on sperm.** *Mol Reprod Dev* 1995, **40**:16-28.
7. Joyce MM, Gonzalez JF, Lewis S, Woldesenbet S, Burghardt RC, Newton GR, Johnson GA: **Caprine uterine and placental osteopontin expression is distinct among epitheliochorial implanting species.** *Placenta* 2005, **26**:160-170.
8. Tuck AB, Hota C, Chambers AF: **Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent.** *Breast Cancer Res Treat* 2001, **70**:197-204.
9. Luedtke CC, McKee MD, Cyr DG, Gregory M, Kaartinen MT, Mui J, Hermo L: **Osteopontin expression and regulation in the testis, efferent ducts, and epididymis of rats during postnatal development through to adulthood.** *Biol Reprod* 2002, **66**:1437-1448.
10. Miwa HE, Gerken TA, Jamison O, Tabak LA: **Isoform-specific O-glycosylation of osteopontin and bone sialoprotein by polypeptide N-acetylgalactosaminyltransferase-1.** *J Biol Chem* 2010, **285**:1208-1219.
11. Shanmugam V, Chackalaparampil I, Kundu GC, Mukherjee AB, Mukherjee BB: **Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells.** *Biochemistry* 1997, **36**:5729-5738.
12. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF: **Osteopontin-c is a selective marker of breast cancer.** *Int J Cancer* 2008, **122**:889-897.
13. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ: **Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.** *J Natl Cancer Inst* 2002, **94**:513-521.
14. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ: **Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies.** *Clin Cancer Res* 2004, **10**:184-190.
15. Chambers AF, Wilson SM, Kerkvliet N, O'Malley FP, Harris JF, Casson AG: **Osteopontin expression in lung cancer.** *Lung Cancer* 1996, **15**:311-323.
16. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF: **Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma.** *Cancer* 2002, **95**:506-512.
17. Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW: **Osteopontin: possible role in prostate cancer progression.** *Clin Cancer Res* 1999, **5**:2271-2277.
18. Liaw L, Lindner V, Schwartz SM, Chambers AF, Giachelli CM: **Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro.** *Circ Res* 1995, **77**:665-672.
19. Philip S, Bulbule A, Kundu GC: **Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells.** *J Biol Chem* 2001, **276**:44926-44935.
20. Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM, Chambers AF: **Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.** *Oncogene* 1999, **18**:4237-4246.
21. Liaw L, Skinner MP, Raines EW, Ross R, Cheresch DA, Schwartz SM, Giachelli CM: **The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro.** *J Clin Invest* 1995, **95**:713-724.
22. Cook AC, Tuck AB, McCarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF: **Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression.** *Mol Carcinog* 2005, **43**:225-236.
23. Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G: **Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis.** *Breast Cancer Res Treat* 2000, **59**:271-278.
24. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM: **NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival.** *J Cell Biol* 1998, **141**:1083-1093.
25. Weintraub AS, Schnapp LM, Lin X, Taubman MB: **Osteopontin deficiency in rat vascular smooth muscle cells is associated with an inability to adhere to collagen and increased apoptosis.** *Lab Invest* 2000, **80**:1603-1615.

26. Folkman J: **Tumor angiogenesis: therapeutic implications.** *N Engl J Med* 1971, **285**:1182-1186.
27. Takano S, Tsuboi K, Tomono Y, Mitsui Y, Nose T: **Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression.** *Br J Cancer* 2000, **82**:1967-1973.
28. Chakraborty G, Jain S, Kundu GC: **Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms.** *Cancer Res* 2008, **68**:152-161.
29. Guo H, Cai CQ, Schroeder RA, Kuo PC: **Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages.** *J Immunol* 2001, **166**:1079-1086.
30. Attur MG, Dave MN, Stuchin S, Kowalski AJ, Steiner G, Abramson SB, Denhardt DT, Amin AR: **Osteopontin: an intrinsic inhibitor of inflammation in cartilage.** *Arthritis Rheum* 2001, **44**:578-584.
31. Beausoleil MS, Schulze EB, Goodale D, Postenka CO, Allan AL: **Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorigenicity, and metastasis.** *BMC Cancer* 2011, **11**:25.
32. Senger DR, Perruzzi CA: **Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin.** *Biochim Biophys Acta* 1996, **1314**:13-24.
33. Mi Z, Oliver T, Guo H, Gao C, Kuo PC: **Thrombin-cleaved COOH(-) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells.** *Cancer Res* 2007, **67**:4088-4097.
34. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos Sergiou A, Peruzzi CA, Detmar M: **Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin.** *Am-J-Pathol* 1996, **149**:293-305, issn: 0002-9440.
35. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, Feng J, Stewart AE, Hu-Lowe DD, Christensen JG: **HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors.** *Cancer Res* 2010, **70**:10090-10100.
36. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF: **Pre- and post-translational regulation of osteopontin in cancer.** *J Cell Commun Signal* 2011, **5**:111-122.
37. Johnston NI, Gunasekharan VK, Ravindranath A, O'Connell C, Johnston PG, El-Tanani MK: **Osteopontin as a target for cancer therapy.** *Front Biosci* 2008, **13**:4361-4372.
38. Isa S, Kawaguchi T, Teramukai S, Minato K, Ohsaki Y, Shibata K, Yonei T, Hayashibara K, Fukushima M, Kawahara M, Furuse K, Mack PC: **Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004.** *J Thorac Oncol* 2009, **4**:1104-1110.
39. Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS: **Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.** *J Clin Oncol* 2010, **28**:936-941.
40. Wu J, Pungaliya P, Kraynov E, Bates B: **Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry.** *Biomarkers* 2012.
41. Politi K, Pao W: **How genetically engineered mouse tumor models provide insights into human cancers.** *J Clin Oncol* 2011, **29**:2273-2281.
42. DuPage M, Dooley AL, Jacks T: **Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase.** *Nat Protoc* 2009, **4**:1064-1072.
43. Kiefer FW, Neschen S, Pfau B, Legerer B, Neuhofer A, Kahle M, Hrabec de Angelis M, Schleder M, Mair M, Kenner L, Plutzky J, Zeyda M, Stulnig TM: **Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice.** *Diabetologia* 2011, **54**:2132-2142.
44. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL: **Altered wound healing in mice lacking a functional osteopontin gene (spp 1).** *J Clin Invest* 1998, **101**:1468-1478.
45. Crawford HC, Matrisian LM, Liaw L: **Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo.** *Cancer Res* 1998, **58**:5206-5215.
46. Nemoto H, Rittling SR, Yoshitake H, Furuya K, Amagasa T, Tsuji K, Nifuji A, Denhardt DT, Noda M: **Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues.** *J Bone Miner Res* 2001, **16**:652-659.
47. Chakraborty G, Jain S, Patil TV, Kundu GC: **Down-regulation of osteopontin attenuates breast tumour progression in vivo.** *J Cell Mol Med* 2008, **12**:2305-2318.
48. Zhao B, Sun T, Meng F, Qu A, Li C, Shen H, Jin Y, Li W: **Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer.** *J Cancer Res Clin Oncol* 2011, **137**:1061-1070.
49. Goparaju CM, Pass HI, Blasberg JD, Hirsch N, Donington JS: **Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer.** *J Thorac Oncol* 2010, **5**:1516-1523.
50. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK: **Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer.** *Lung Cancer* 2007, **57**:373-380.
51. Blasberg JD, Goparaju CM, Pass HI, Donington JS: **Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity.** *J Thorac Cardiovasc Surg* 2010, **139**:1587-1593.
52. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ, Gandara DR: **Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.** *J Clin Oncol* 2008, **26**:4771-4776.
53. Meuwissen R, Berns A: **Mouse models for human lung cancer.** *Genes Dev* 2005, **19**:643-664.
54. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR: **The Catalogue of Somatic Mutations in Cancer (COSMIC).** *Curr Protoc Hum Genet* 2008, **Chapter 10**, **Unit 10 11**.
55. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH, Rigas J, Seymour L, Winton T, Shepherd FA: **Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.** *J Clin Oncol* 2007, **25**:5240-5247.

doi:10.1186/1756-9966-31-26

Cite this article as: Shojaei et al.: Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. *Journal of Experimental & Clinical Cancer Research* 2012 **31**:26.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

